Losartan Potassium Tablet
Product Images NDC 70518-3282

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 70518-3282). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium 50mg 70518 3282 01

Losartan Potassium 50 mg tablets packaging label showing a quantity of 30 tablets. The label includes the product name, dosage strength, and mentions repackaging by RemedyRepack Inc. It also notes the original manufacturer Lupin Pharma, Baltimore, MD. Storage instructions specify keeping the medication out of reach of children and temperature recommendations.*

FDA Label Image

Remedy_label (Remedy Label)

Losartan Potassium 50 mg tablet packaging label showing a quantity of 60 tablets. The label includes the product name, strength, dosage form, and mentions Remedy Repack as the repackager with manufacturer Lupin Pharma in Baltimore, MD. Directions and storage instructions are present, along with NDC 70518-3282-00.*

FDA Label Image

Image (A27c3ddf 3129 4f3e Bc0e 37381cc1a167 01)

Chemical structure of Losartan Potassium, showing its molecular arrangement with atoms and bonds including a potassium ion (K+).*

FDA Label Image

Image (A27c3ddf 3129 4f3e Bc0e 37381cc1a167 02)

A line graph comparing the percentage of patients with a primary endpoint over 66 study months between Atenolol (dotted line) and Losartan (solid line). The graph depicts a slightly lower event rate for Losartan, with an adjusted risk reduction of 13% (p=0.021) noted at the bottom.*

FDA Label Image

Image (A27c3ddf 3129 4f3e Bc0e 37381cc1a167 03)

A line graph comparing the percentage of patients with fatal or non-fatal strokes over study months between Atenolol and Losartan treatments. The horizontal axis represents the study duration in months (0 to 66), and the vertical axis shows the percentage of patients affected (0 to 8%). Losartan demonstrates a lower stroke rate than Atenolol, with an annotated adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Image (A27c3ddf 3129 4f3e Bc0e 37381cc1a167 04)

A forest plot comparing the event rates and hazard ratios for Losartan versus Atenolol in primary composite and stroke (fatal/non-fatal) outcomes. The chart breaks down data by patient numbers, age, gender, race, ISH, diabetes, and history of CVD, displaying hazard ratios with 95% confidence intervals to indicate which treatment is favored across these categories.*

FDA Label Image

Image (A27c3ddf 3129 4f3e Bc0e 37381cc1a167 05)

A line graph comparing the percentage of patients with an event over 48 months between Losartan and placebo groups. The graph shows a risk reduction of 16.1% with a p-value of 0.022. The x-axis represents time in months, and the y-axis represents the percentage of patients with the event.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.